Inactive Instrument

Cell Source Inc Stock OTC Bulletin Board

US15114L1044

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

05-14	Cell Source, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
04-07	Cell Source, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

on all subscriptions*

Last hours

Enjoy this offer

* See conditions under "Our services"

Cell Source, Inc. is a cell therapy company focused on immunotherapy. The Company is primarily focused on the development of immune system management technology (Veto Cell technology). Its lead prospective product is its Veto Cell immune system management technology. Its Veto Cell technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is in pre-clinical phase, and its data shows that it provides results in allogeneic (donor-derived) hematopoietic stem cell transplantation (HSCT) by allowing for haploidentical stem cell transplants under a mild conditioning regimen. Its product pipeline includes chimeric antigen receptor (CAR) T-cell therapies, which include VETO CAR-T (with or without HSCT) for B-cell malignancies, Veto Cell kidney transplants, VETO CAR-T for solid tumors, Veto Cell liver transplants, and Veto HSCT for non-malignant disorders. The Company's wholly owned subsidiary is Cell Source Limited (CSL).

Employees

Sector

Biotechnology & Medical Research

More about the company

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!

SEIZE THE OFFER!

Market Cap	24.41M 21.04M 19.37M 18.19M 34.15M 2.31B 34.51M 229M 89.18M 1.13B 91.61M 89.66M 3.92B	P/E 2023	-2.65x	P/E 2024	-2.49x
Enterprise Value	34.92M 30.09M 27.71M 26.02M 48.85M 3.3B 49.36M 327M 128M 1.62B 131M 128M 5.6B	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	45.62%	Yield 2023 *	-	Yield 2024	-

05-14	Cell Source, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
04-07	Cell Source, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
04-06	Cell Source, Inc. Auditor Raises 'Going Concern' Doubt	CI
24-11-21	Cell Source, Inc. Shared Positive Interim Results from Its Phase 1/2 First-In-Human Clinical Trial Conducted At the University of Texas Md Anderson Cancer Center	CI
24-11-14	Cell Source, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-08-19	Cell Source, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-07-29	Cell Source, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
24-06-24	Cell Source, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-06-23	Cell Source, Inc. Auditor Raises 'Going Concern' Doubt	CI
24-03-21	Cell Source, Inc. announced that it has received $4.76017 million in funding	CI
23-11-09	Cell Source, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
23-09-19	Cell Source, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
23-08-23	Cell Source, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

05-21	Cell Source Presented Its Breakthrough Developments for Mismatched Donor Stem Cell and Organ Transplants and Off-the-shelf CAR-T Cell Therapy at the LD Micro Invitational Conference in Los Angeles This Week	AQ
05-14	Cell Source, Inc. to Present at the LD Micro Invitational XVI	NE
05-14	Cell Source : Quarterly Report for Quarter Ending March 31, 2025 (Form 10-Q)	PU
04-07	Cell Source : Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K)	PU
22-12-08	Note 2 - Going Concern and Management Plans	AQ

Director	Title	Age	Since
Dennis Brown CHM	Chairman	77	2015-05-17
Darlene Soave BRD	Director/Board Member	82	2021-03-24
George Verstraete BRD	Director/Board Member	72	2022-03-09

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARGENX SE	+1.64%	+0.68%	+62.48%	+113.33%	54.54B
WUXI APPTEC CO., LTD.	-1.22%	+5.01%	+43.38%	+36.69%	43.86B
BIONTECH SE	-1.43%	+3.47%	-15.83%	-20.48%	22.63B
INSMED INCORPORATED	-1.99%	-3.55%	-5.97%	+377.60%	20.7B
WUXI BIOLOGICS (CAYMAN) INC.	-0.53%	+0.54%	+16.19%	-36.06%	15.84B
GENMAB A/S	+3.42%	+0.12%	+11.73%	-39.06%	14.83B
EXELIXIS, INC.	-1.70%	-1.68%	+24.79%	+172.92%	13.1B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-5.17%	+0.50%	+21.80%	-	12.66B
MADRIGAL PHARMACEUTICALS, INC.	+0.29%	+5.10%	+75.82%	+105.33%	11.56B
Average	-0.74%	+0.18%	+26.04%	+88.78%	23.3B
Weighted average by Cap.	-0.38%	+0.18%	+32.12%	+88.69%

Cell Source Inc Stock OTC Bulletin Board

Stocks

US15114L1044

Biotechnology & Medical Research

Valuation: Cell Source Inc

Latest news : Cell Source Inc

Press Releases: Cell Source Inc

Managers and Directors: Cell Source Inc

Bio Therapeutic Drugs

Financials

Company Profile

	2023	2024
Net sales	-	-
Net income	-5.32M -4.59M -4.22M -3.96M -7.44M -503M -7.52M -49.9M -19.44M -246M -19.97M -19.55M -854M	-4.51M -3.89M -3.58M -3.36M -6.31M -427M -6.38M -42.32M -16.49M -209M -16.94M -16.58M -724M
Net Debt	9.27M 7.99M 7.36M 6.91M 12.97M 877M 13.11M 86.97M 33.88M 429M 34.8M 34.07M 1.49B	10.51M 9.06M 8.34M 7.83M 14.7M 993M 14.86M 98.54M 38.39M 487M 39.44M 38.6M 1.69B